SCHEMBL911112

SCHEMBL911112

COB(OC)c1ccccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
ACHE P22303 2/20 0.43
ENPP2 Q13822 1/20 0.38
ORAI1 Q96D31 1/20 0.37
ORAI2 Q96SN7 1/20 0.37
ORAI3 Q9BRQ5 1/20 0.37
ALDH1A1 P00352 4/20 0.36
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA7 P43166 3/20 0.35
CA9 Q16790 3/20 0.35
ESR1 P03372 1/20 0.34
CYP3A4 P08684 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP2A6 P11509 2/20 0.32
CYP1A2 P05177 2/20 0.32
CA4 P22748 2/20 0.32
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5951494 0.81 TRPA1 (0.39) TSHRACHEENPP2ALDH1A1CA1
SCHEMBL28994175 0.80 TSHR (0.43) TSHRACHEENPP2ORAI1ORAI2
SCHEMBL14703738 0.78 ENPP2 (0.46) TSHRACHEENPP2ORAI1ORAI2
SCHEMBL22000805 0.75 TSHR (0.38) TSHRACHEALDH1A1CA1CA2
SCHEMBL5953252 0.73 ENPP2 (0.64) TSHRENPP2ORAI1ORAI2ORAI3
SCHEMBL12424043 0.73 ALDH1A1 (0.44) TSHRENPP2ORAI1ORAI2ORAI3
SCHEMBL19929264 0.73 CA2 (0.44) TSHRENPP2ORAI1ORAI2ORAI3
SCHEMBL126881 0.73 TSHR (0.53) TSHRACHEALDH1A1CA1CA2
SCHEMBL7181071 0.72 TSHR (0.45) TSHRACHEENPP2ORAI1ORAI2
SCHEMBL13052533 0.72 CYP2A6 (0.39) TSHRACHEALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115928264-A Preparation method of metal-containing near-stoichiometric continuous silicon carbide fiber 湖南泽睿新材料有限公司 2023-04-07 CN claimed
US-8921299-B2 Detergents having acceptable color THE PROCTER & GAMBLE COMPANY (US) 2014-12-30 US claimed
CN-119716054-A Fluorescent paper chip for detecting staphylococcus aureus and preparation method and application thereof 南京师范大学 2025-03-28 CN disclosed
CN-119716050-A Fluorescent paper chip for detecting escherichia coli O157: H7 as well as preparation method and application thereof 南京师范大学 2025-03-28 CN disclosed
CN-119192137-A Inhibition of human integrin alpha4β7 莫菲克医疗股份有限公司 2024-12-27 CN disclosed
CN-112682031-B Oil field interwell tracer, tracing method and fracturing fluid 中国石油化工股份有限公司 2024-06-28 CN disclosed
WO-2024126697-A1 HIGH STRENGTH LIQUID PROTEASE FORMULATIONS NOVOZYMES A/S (DK) 2024-06-20 WO disclosed
EP-4379029-A1 POLYPEPTIDES AND COMPOSITIONS COMPRISING SUCH POLYPEPTIDES Novozymes A/S (DK) 2024-06-05 EP disclosed
EP-3647398-B1 CLEANING COMPOSITIONS CONTAINING DISPERSINS V HENKEL AG & CO KGAA (DE) 2024-05-15 EP disclosed
US-20240132808-A1 Storage-Stable Hydrolase Containing Liquids BASF SE (DE) 2024-04-25 US disclosed
EP-4305146-A1 POLYPEPTIDE VARIANTS Novozymes A/S (DK) 2024-01-17 EP disclosed
EP-1924677-A1 STABILIZATION OF CONCENTRATED LIQUID ENZYME ADDITIVES Novozymes A/S (DK) 2008-05-28 EP disclosed
US-20070060493-A1 Stabilization of concentrated liquid enzyme additives NOVOZYMES A/S (DK) 2007-03-15 US disclosed
WO-2007025549-A1 STABILIZATION OF CONCENTRATED LIQUID ENZYME ADDITIVES NOVOZYMES A/S (DK) 2007-03-08 WO disclosed
EP-1341793-B1 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2007-01-17 EP disclosed
US-20040266799-A1 CRF receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. 2004-12-30 US disclosed
US-6747034-B2 CORTICOTROPIN-RELEASING FACTOR (CRF); SUCH AS 4-CHLORO-2-METHYL-5-NITRO-8-(2,4-DICHLORO)PHENYL-1,7-NAPHTHYRIDINE FOR TREATING STROKE, ANXIETY, DEPRESSION, AND/OR IRRITABLE BOWEL SYNDROME NEUROCRINE BIOSCIENCES, INC. 2004-06-08 US disclosed
EP-1341793-A2 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO Neurocrine Biosciences, Inc. (US) 2003-09-10 EP disclosed
US-20020151557-A1 CRF receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC 2002-10-17 US disclosed
WO-2002040480-A2 CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266799-A1 CRF receptor antagonists and methods relating thereto CRHR1, CRH, CRHR2 TSHR 162/4885ACHE 2077/4885ENPP2 421/4885
US-20020151557-A1 CRF receptor antagonists and methods relating thereto CRHR1, CRH, CRHR2 TSHR 162/4885ACHE 2077/4885ENPP2 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.